Mode
Text Size
Log in / Sign up
N/A N=33 Treatment

Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.

Warts · Plantar Wart · Common Wart

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Diameter of the Wart — -0.12 cm

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Sérum VERRUPRO (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Swiss Footcare Laboratories - Poderm Professional
Primary completion
Aug 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Diameter of the Wart
-0.12
SECONDARY
Global Improvement of the Wart
15; 12; 4; 1
SECONDARY
Roughness of the Wart
-1.4
SECONDARY
Thickness of the Wart
-1.5
SECONDARY
Number of Dermal Papillae
-4.1
SECONDARY
Number of Participants Who Participated in Photography Session
32
SECONDARY
Patient Evaluation
8; 9; 11; 4; 0
SECONDARY
Adverse Event
SECONDARY
Product Tolerance
18; 9; 3; 1; 1

Summary

The principal aim of this study is to evaluate the efficacy and the safety of the tested product on common and plantar wart after 35 days of treatment. For this study, 33 patients presenting at least one common wart on the fingers, back on the hand or a plantar wart of a size between 0.1 and 0.5cm and present since less than 6 months will be included to reach this objective

Eligibility Criteria

Inclusion Criteria

Patient having given freely her/his informed, written consent. Patient having a good general health. Age: more than 18 years. Patient cooperative and aware of the device's modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.

Patient being psychologically able to understand information and to give his/her consent.

Patient presenting at least 1 common wart, present since less than 6 months, on the fingers, back of the hands (60% of patients) and/or at least 1 plantar wart (40% of patients).

Patient presenting wart of a size between 0,1 and 0,5 cm. Women of childbearing potential should use an accepted contraceptive regimen (at the Investigator's discretion) since at least 12 weeks before the beginning of the study and during all the study.

Exclusion Criteria

For plantar wart: wart on the point of support. Wart with keratosis. Wart in mosaic. Pregnant or nursing woman or planning a pregnancy during the investigation. Patient considered by the investigator likely to be non-compliant with the protocol.

Patient enrolled in another clinical trial during the test period. Patient having a known allergy or hypersensitivity to one of the constituents of the tested products.

Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.

Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, immunocompromised patient HIV, psoriasis, lichen planus, immunosuppressive pathology, chronic venous insufficiency, Peripheral Arterial Obstructive Disease, delay or lack of ungual growth … Patient with cutaneous pathology on studied zone other than warts.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06214559). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search